DARBID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DARBID (DARBID).
Antimuscarinic agent; competitively blocks acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretions.
| Metabolism | Hepatic metabolism (minimal); primarily excreted unchanged in urine. |
| Excretion | Renal: ~50% unchanged; biliary/fecal: ~50% as metabolites and unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 1.5 to 2 hours in adults, requiring frequent dosing for sustained anticholinergic effect. |
| Protein binding | Approximately 20-30% bound to albumin. |
| Volume of Distribution | Approximately 1.0-1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 30-50% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; IM: 15-30 minutes; IV: 5-10 minutes. |
| Duration of Action | Oral: 3-4 hours; IM/IV: 2-3 hours. Clinical effects on gastric secretion may persist up to 6 hours. |
5 mg orally three times daily, before meals. May be increased to 20 mg per day if necessary.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (eGFR <30 mL/min) due to anticholinergic effects. |
| Liver impairment | No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for increased anticholinergic effects. |
| Pediatric use | Safety and efficacy not established; not recommended for pediatric use. |
| Geriatric use | Start at 5 mg orally twice daily; increase cautiously due to increased risk of anticholinergic side effects (cognitive impairment, constipation, urinary retention). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DARBID (DARBID).
| Breastfeeding | Scant data; M/P ratio unknown. Excreted in breast milk in small amounts. Monitor infant for anticholinergic effects (dry mouth, constipation, urinary retention). Use only if clearly needed, especially in neonates or preterm infants. |
| Teratogenic Risk | Pregnancy Category C. In first trimester, limited human data; animal studies show increased risk of skeletal anomalies at high doses. Second and third trimesters: potential for decreased fetal heart rate variability and anticholinergic effects (tachycardia, ileus). Avoid in preterm labor due to possible association with neonatal seizures. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Glaucoma (narrow-angle)","Obstructive uropathy (e.g., bladder neck obstruction due to prostatic hyperplasia)","Obstructive disease of the gastrointestinal tract (e.g., pyloroduodenal stenosis)","Severe ulcerative colitis","Myasthenia gravis","Hiatal hernia associated with reflux esophagitis"]
| Precautions | ["May cause heat prostration in hot environments due to decreased sweating","Caution in glaucoma, pyloric obstruction, prostatic hypertrophy, and hiatal hernia associated with reflux esophagitis","May cause drowsiness or blurred vision"] |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor heart rate, blood pressure, urinary retention, and mental status. Fetal: Heart rate monitoring for tachycardia; consider ultrasound for growth if used long-term. |
| Fertility Effects | No human studies. Animal data show no major reproductive toxicity. Theoretical anticholinergic effects may alter vaginal secretions or impair uterine contractility during labor. |